Navigation Links
PPD Opens Offices in Sydney, Australia; Copenhagen, Denmark; Lima, Peru; and Lisbon, Portugal

Expands global footprint for drug development services

WILMINGTON, N.C., Oct. 23 /PRNewswire-FirstCall/ -- PPD, Inc. (Nasdaq: PPDI) today announced the opening of offices in Sydney, Australia; Copenhagen, Denmark; Lisbon, Portugal; and Lima, Peru; reflecting continued expansion of its Phase II-IV services in key therapeutic areas.

The four new offices broaden the company's global footprint for delivering clinical services in response to increasing client demand. With an office in Melbourne, Sydney is PPD's second location in Australia. Offices in Copenhagen, Lisbon and Lima establish PPD's physical presence in those countries.

"With the biopharmaceutical industry increasingly relying on outsourcing, these new offices are important to our strategic growth in areas where there is high demand for our global experience and therapeutic expertise," said Fred Eshelman, chief executive officer of PPD. "We will continue to execute our globalization strategy by positioning our people, systems and infrastructure in locations that meet the needs of our clients."

PPD's Sydney office is based at 1 Pacific Highway, North Sydney, and the Copenhagen office is at Regus South Harbour at Sluseholmen 2-4. The Lisbon office is at Avenida da Liberdade, 110-1, and the Lima office is located at the Centro Empresarial Real -- San Isidro Edificio Real Seis, Piso 7. For more information about PPD services provided at Sydney, Copenhagen and Lisbon, call +1 919 456 4402, and for Lima, call +1 910 558 6789.

PPD is a leading global contract research organization providing discovery, development and post-approval services as well as compound partnering programs. Our clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 30 countries and more than 10,000 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a commitment to quality to help its clients and partners maximize returns on their R&D investments and accelerate the delivery of safe and effective therapeutics to patients. For more information, visit our Web site at

Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions about the opening of new offices and our globalization strategy, contained in this news release are forward-looking statements that involve a number of risks and uncertainties. Although PPD attempts to be accurate in making those forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. In addition, other important factors which could cause results to differ materially include the following: economic conditions and outsourcing trends in the pharmaceutical, biotechnology and medical device industries and government-sponsored research sector; loss of or delay in large contracts; dependence on collaborative relationships; rapid technological advances that make our products and services less competitive; risks associated with acquisitions and investments, such as impairments; competition within the outsourcing industry; continued success in sales growth; the ability to attract and retain key personnel; and the other risk factors set forth from time to time in the SEC filings for PPD, copies of which are available free of charge upon request from the PPD investor relations department.



Sue Ann Pentecost

+919 456 5890


Steve Smith

+910 558 7585

Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. MaxCyte and Medinet to Present at the 13th Annual Meeting of the International Society for Cellular Therapy (ISCT) in Sydney, Australia
Post Your Comments:
(Date:11/26/2015)... 26 november 2015 AAIPharma Services ... geplande investering aan van ten minste $15,8 ... en het mondiale hoofdkantoor in ... resulteren in extra kantoorruimte en extra capaciteit ... groeiende behoeften van de farmaceutische en biotechnologische ...
(Date:11/26/2015)... November 26, 2015 ... nieuwe aanpak combineert immunotherapie met Bremachlorin-photodynamische therapie ... ) --> ... (Photo: ) ... Medisch Centrum (LUMC) blijkt ...
(Date:11/26/2015)... Research and Markets ( ) has announced the addition ... 2019 - Rise in Cardiac Disorders and Growing Awareness among ... offering. Boston scientific and ... and others. --> The market is dominated ... scientific and others. Asia ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... November 27, 2015 , ... A simply groundbreaking television series, "Voices in ... that delves into an array of issues that are presently affecting Americans. Dedicated to ... dialogue, this show is changing the subjects consumers focus on, one episode at a ...
(Date:11/27/2015)... CA (PRWEB) , ... November 27, 2015 , ... ... California Medical Associates, Inc. and Dr. Tucker Bierbaum with Emergency Medicine at ... They observed that both STEMI and Sepsis conditions present in similar ways and require ...
(Date:11/26/2015)... , ... November 26, 2015 , ... ... real-time eReferral system for diagnostic imaging in the Waterloo region. Using the Ocean ... Nuclear Medicine tests directly from their electronic medical record (EMR) without the need ...
(Date:11/26/2015)... ... November 26, 2015 , ... ... process, participated in the 61st annual Employee Benefits Conference. The Employee Benefits Conference ... Sunday, November 8th through Wednesday, November 11th, 2015. The conference was held at ...
(Date:11/25/2015)... Indianapolis, IN (PRWEB) , ... November 25, 2015 ... ... clean water accessible for all, Water For Empowerment ™ attracts volunteers together ... on clean water by empowering women as key stakeholders in the process. The ...
Breaking Medicine News(10 mins):